Neutrophil-Mediated Delivery Platforms for Synergistic Chemo-Immunotherapy of Non-Small-Cell Lung Cancer Therapy
Source abstract
Abstract
Traditional nanocarriers possess good therapeutic efficacy in the treatment of non-small-cell lung cancer (NSCLC), but usually suffer from high immunogenicity, poor biosafety, and low targeting. In this work, a neutrophil-mediated delivery platform constructed from neutrophils (NEs) and paclitaxel/transforming growth factor-β (TGF-β) siRNA loaded cationic liposome, namely, siTGFβ-PLP-NEs, is fabricated for the combination therapy of NSCLC via synergistic chemo-immunotherapy. siTGFβ-PLP-NEs can be targeted to the tumor site and effectively release paclitaxel and siTGFβ, which is conducive to simultaneously inhibiting the proliferation of tumor cells and the expression of TGF-β. The experimental results demonstrate that siTGFβ-PLP-NEs can prevent the transition of tumor-associated NEs from an anti-tumor (N1) phenotype to a pro-tumor (N2) phenotype, enhance CD8 + T cell infiltration, and reduce regulatory T cell (Treg) infiltration, which provides a great promising combination therapy option to use neutrophil-mediated systems as a general-purpose delivery platform for the treatment of NSCLC.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Life Sciences, Jilin University, 2699 Qianjin Street, Changchun 130012, P. R. China
Funding
Department of Science and Technology of Jilin Province · Ministry of Science and Technology of the People's Republic of China
References (53)
Show source-provided references
1. 10.1056/NEJMoa191662310.1056/NEJMoa1916623 ↗
2. 10.1016/S0140-6736(21)00312-310.1016/S0140-6736(21)00312-3 ↗
3. 10.7150/thno.8068710.7150/thno.80687 ↗
4. 10.1038/s41591-021-01450-210.1038/s41591-021-01450-2 ↗
5. 10.1016/j.jtho.2019.01.00610.1016/j.jtho.2019.01.006 ↗
6. 10.1002/smll.20210769010.1002/smll.202107690 ↗
7. 10.7150/ijbs.7095810.7150/ijbs.70958 ↗
8. 10.1186/s13045-020-00881-710.1186/s13045-020-00881-7 ↗
9. 10.1200/JCO.2008.17.716210.1200/JCO.2008.17.7162 ↗
10. 10.1021/acs.nanolett.0c0227210.1021/acs.nanolett.0c02272 ↗
11. 10.1016/j.pharmthera.2014.11.00110.1016/j.pharmthera.2014.11.001 ↗
12. 10.1186/s13578-017-0168-010.1186/s13578-017-0168-0 ↗
13. 10.1016/j.pharmthera.2017.11.00410.1016/j.pharmthera.2017.11.004 ↗
14. 10.1186/s12951-024-02883-w10.1186/s12951-024-02883-w ↗
15. 10.1038/s41392-020-00449-410.1038/s41392-020-00449-4 ↗
16. 10.1021/acs.nanolett.3c0207510.1021/acs.nanolett.3c02075 ↗
17. 10.1186/s13045-021-01187-y10.1186/s13045-021-01187-y ↗
18. 10.1016/j.jconrel.2023.08.02010.1016/j.jconrel.2023.08.020 ↗
19. 10.1038/nature1440710.1038/nature14407 ↗
20. 10.1038/s41467-023-37872-410.1038/s41467-023-37872-4 ↗
21. 10.1038/s41571-019-0222-410.1038/s41571-019-0222-4 ↗
22. 10.1016/j.apsb.2022.08.01210.1016/j.apsb.2022.08.012 ↗
23. 10.1016/j.bbcan.2022.18876210.1016/j.bbcan.2022.188762 ↗
24. 10.1038/s41467-023-37515-810.1038/s41467-023-37515-8 ↗
25. 10.1038/s41568-021-00413-610.1038/s41568-021-00413-6 ↗
26. 10.1038/s41467-022-31141-610.1038/s41467-022-31141-6 ↗
27. 10.1021/acsnano.9b0971310.1021/acsnano.9b09713 ↗
28. 10.1016/j.cell.2023.02.03210.1016/j.cell.2023.02.032 ↗
29. 10.1038/d41586-020-01672-310.1038/d41586-020-01672-3 ↗
30. 10.3389/fimmu.2021.70877010.3389/fimmu.2021.708770 ↗
31. 10.1002/advs.20210524010.1002/advs.202105240 ↗
32. 10.1016/j.ccr.2005.10.01210.1016/j.ccr.2005.10.012 ↗
33. 10.1016/j.immuni.2006.07.01110.1016/j.immuni.2006.07.011 ↗
34. 10.1038/ni154910.1038/ni1549 ↗
35. 10.1038/nature0875010.1038/nature08750 ↗
36. 10.1186/s12943-022-01569-x10.1186/s12943-022-01569-x ↗
37. 10.1007/s12307-014-0147-510.1007/s12307-014-0147-5 ↗
38. 10.1158/1078-0432.CCR-16-204710.1158/1078-0432.CCR-16-2047 ↗
39. 10.1016/j.intimp.2010.11.02110.1016/j.intimp.2010.11.021 ↗
40. 10.1038/s41598-018-30417-610.1038/s41598-018-30417-6 ↗
41. 10.1016/j.ijrobp.2021.07.84510.1016/j.ijrobp.2021.07.845 ↗
42. 10.1111/imr.1317610.1111/imr.13176 ↗
43. 10.1016/j.jconrel.2024.09.03710.1016/j.jconrel.2024.09.037 ↗
44. 10.1111/j.1470-8744.1990.tb00099.x10.1111/j.1470-8744.1990.tb00099.x ↗
45. 10.1016/j.apsb.2022.02.02310.1016/j.apsb.2022.02.023 ↗
46. 10.1016/j.xcrm.2025.10220510.1016/j.xcrm.2025.102205 ↗
47. 10.1038/s41571-024-00959-y10.1038/s41571-024-00959-y ↗
48. 10.1016/j.apmt.2024.10225910.1016/j.apmt.2024.102259 ↗
49. 10.1016/j.celrep.2022.11112810.1016/j.celrep.2022.111128 ↗
50. 10.1016/j.lfs.2023.12202110.1016/j.lfs.2023.122021 ↗
51. 10.1016/j.ccell.2023.03.00810.1016/j.ccell.2023.03.008 ↗
52. 10.1182/blood-2018-11-84454810.1182/blood-2018-11-844548 ↗
53. 10.1016/j.immuni.2020.03.00110.1016/j.immuni.2020.03.001 ↗